SUPPLEMENTAL FIGURES S1-S2
SUPPLEMENTAL TABLES S1-S2 (+ Refs)
Fig. S1

Fig. S2

Carcinogenesis: Path(s) to Cancer Genesis & Progression

Key: One-way route □□ Two-way route □□□ Dead end only □
<table>
<thead>
<tr>
<th></th>
<th>Evasion of Anti-growth Signalling</th>
<th>Angiogenesis</th>
<th>Genetic Instability</th>
<th>Resistance to Cell Death</th>
<th>Immune System Evasion</th>
<th>Replicative Immortality</th>
<th>Sustained Proliferative Signalling</th>
<th>Tissue Invasion and Metastasis</th>
<th>Tumor Promoting Inflammation</th>
<th>Tumor Microenvironment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glycolysis</strong></td>
<td>-</td>
<td>+ (4,5)</td>
<td>Unknown</td>
<td>+ (6-11)</td>
<td>+ (12,13)</td>
<td>+ (14-16)</td>
<td>+ (17,18)</td>
<td>+ (19-22)</td>
<td>+ (23-26)</td>
<td>+ (27,28)</td>
</tr>
<tr>
<td><strong>Pyruvate dehydrogenase (PDH)</strong></td>
<td>-</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>- (31)</td>
<td>- (32)</td>
<td>- (33)</td>
<td>+ (34)</td>
<td>- (35)</td>
</tr>
<tr>
<td><strong>TCA Cycle</strong></td>
<td>-</td>
<td>+ (38)</td>
<td>+ (39)</td>
<td>- (10)</td>
<td>Unknown</td>
<td>- (31)</td>
<td>- (40)</td>
<td>+ (21)</td>
<td>+ (41)</td>
<td>+ (42)</td>
</tr>
<tr>
<td><strong>Electron Transport Chain</strong></td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>- (43)</td>
<td>Unknown</td>
<td>- (44)</td>
<td>+ (45)</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lipid Metabolism</strong></td>
<td>-</td>
<td>+ (51)</td>
<td>+ (52,53)</td>
<td>Unknown</td>
<td>+ (54-57)</td>
<td>± (58-62)</td>
<td>+ (63,64)</td>
<td>- (65-67)</td>
<td>+ (68,69)</td>
<td>+ (70,71)</td>
</tr>
<tr>
<td><strong>Increased ROS</strong></td>
<td>± (72,73)</td>
<td>+ (74)</td>
<td>+ (75)</td>
<td>+ (76)</td>
<td>+ (77)</td>
<td>± (78-80)</td>
<td>+ (81)</td>
<td>± (82-84)</td>
<td>+ (85)</td>
<td>± (86)</td>
</tr>
<tr>
<td><strong>mTOR Signaling</strong></td>
<td>- (87,88)</td>
<td>+ (89)</td>
<td>Unknown</td>
<td>+ (90-92)</td>
<td>+ (93)</td>
<td>± (94-96)</td>
<td>+ (97)</td>
<td>+ (98-100)</td>
<td>+ (101)</td>
<td>+ (102)</td>
</tr>
<tr>
<td><strong>Gluconeogenesis</strong></td>
<td>- (26)</td>
<td>+ (103)</td>
<td>+ (104)</td>
<td>- (105)</td>
<td>Unknown</td>
<td>- (106)</td>
<td>+ (107)</td>
<td>Unknown</td>
<td>+ (26)</td>
<td>+ (108)</td>
</tr>
</tbody>
</table>

Table S1.
<table>
<thead>
<tr>
<th>Dysregulated Metabolism – Prototypical Disruptor Candidates</th>
<th>Evasion of Anti-growth Signalling</th>
<th>Angiogenesis</th>
<th>Genetic Instability</th>
<th>Immune System Evasion</th>
<th>Resistance to Cell Death</th>
<th>Replicative Immortality</th>
<th>Sustained Proliferative Signalling</th>
<th>Tissue Invasion and Metastasis</th>
<th>Tumor Promoting Inflammation</th>
<th>Tumor Microenvironment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cypermethrin</td>
<td>Unknown</td>
<td>Unknown</td>
<td>+ (109)</td>
<td>Unknown</td>
<td>+ (110)</td>
<td>Unknown</td>
<td>+ (111,112)</td>
<td>+ (113)</td>
<td>+ (113)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Acrolein</td>
<td>± (114,115)</td>
<td>− (116)</td>
<td>+ (117)</td>
<td>Unknown</td>
<td>± (118)</td>
<td>± (119,120)</td>
<td>− (121,122)</td>
<td>+ (123)</td>
<td>+ (115,124)</td>
<td>− (125)</td>
</tr>
<tr>
<td>Rotenone</td>
<td>− (126)</td>
<td>Unknown</td>
<td>+ (127)</td>
<td>Unknown</td>
<td>− (128)</td>
<td>± (129,130)</td>
<td>− (126,131)</td>
<td>− (132)</td>
<td>− (126)</td>
<td>+ (133)</td>
</tr>
<tr>
<td>Metals (e.g. Cadmium, Chromium, Copper, Iron, and Nickel)</td>
<td>± (134-139)</td>
<td>± (140,141)</td>
<td>+ (142)</td>
<td>+ (143)</td>
<td>± (144-146)</td>
<td>± (147-151)</td>
<td>± (152-158)</td>
<td>± (159-167)</td>
<td>+ (153,168-172)</td>
<td>+ (164,173-176)</td>
</tr>
<tr>
<td>Hexythiazox</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Organophosphates (e.g. Diazinon and Malathion)</td>
<td>+ (177)</td>
<td>+ (178)</td>
<td>+ (179,180)</td>
<td>Unknown</td>
<td>− (181)</td>
<td>− (182)</td>
<td>± (181,183)</td>
<td>Unknown</td>
<td>+ (184,185)</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Table S2.

Cross-Validation Table References (Tables S1 and S2)


